Given the role of IL-1β in the development/progression of ischemic brain injury and the success of A151 in ameliorating multiple diseases with inflammatory components, we sought to examine the effect of A151 on critical processes (i.e. inflammasome mediated responses) underlying the pathophysiology of brain ischemia via the synergistic use of both oxygen-glucose deprivation (OGD) and lipopolysaccharide (LPS) stimulation in a reductionist in vitro system which is intended to replicate the complex pathobiology that unfolds during an ischemic stroke. Here, IL1B is linked to brain ischemia.